贝瑞基因：业务一直聚焦生育健康领域

Core Viewpoint - The company, Berry Genomics (000710), focuses on the reproductive health sector, achieving significant commercial effects in the prenatal testing market while the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [1] Group 1 - The company plans to expand its complex genetic testing services into more areas, leveraging artificial intelligence applications and years of experience in third-generation sequencing technology [1] - The company aims to provide more health services directly to the consumer (C-end) by integrating clinical medical data in the future [1] - The recent changes in major shareholder equity do not impact the company's business development [1]